Spain Bioceramics Market Overview, 2031

Key Insights

• The e Spanish bioceramics market operates within a distinctive healthcare environment characterized by a deeply entrenched public healthcare system, a pioneering regional arthroplasty registry, and a mature dental implant market that ranks among the highest in the world for per capita penetration. Osteoarthritis (OA) affects approximately 7 million people in Spain, with prevalence increasing with age. The condition is more prevalent in women (35.6%) compared to men (29.4%), with the most affected age group between 55 and 75 years (53.5%). Rheumatic diseases, including osteoarthritis, affect more than 11 million adults in Spain, making them the leading cause of permanent disability due to illness ahead of cardiovascular, respiratory, or neurological diseases. Spain ranks among the top European countries for the number of prostheses implanted across all joints and for the level of implant reliability. In the dental sector, Spain remains one of the countries with the highest number of implants per inhabitant worldwide, with more than 2.1 million dental implants placed in 2024 alone, representing more than 17 million implants placed in the last decade.
• Spain's healthcare delivery model for Bioceramics devices is distinguished by a unique decentralized approach to implant surveillance, with the recent launch of the first fully operational regional arthroplasty registry. The Registro de Artroplastias de Galicia (RAGal), activated on January 2, 2026, represents Spain's first comprehensive, computerized regional registry of hip, knee, and shoulder prostheses. Developed by the Sociedad Gallega de Cirugía Ortopédica y Traumatología (SOGACOT) in collaboration with the Servizo Galego de Saúde (Sergas), RAGal enables early detection of potential implant failures, identification of complication patterns, and complete traceability of each implant. The registry is designed to allow comparison of outcomes between centers and professionals, promote evidence based best practices, and facilitate the Sergas in forecasting future needs. The registry is based on established models from Sweden and England among the world's most experienced arthroplasty registries and SOGACOT aims to promote similar registries in other autonomous communities. While Catalonia has a previous registry experience, it was not computerized nor did it include shoulder implants. Beyond these regional efforts, multiple arthroplasty registries exist within the Spanish National Health System (SNS), with the first studies from these databases including 280,201 hip prostheses and 151,814 knee prostheses.
• Regulatory oversight for medical devices in Spain is provided by the Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), which operates under the EU Medical Device Regulation (MDR) while maintaining specific national obligations. Medical devices must bear CE marking and be registered with the AEMPS database. AEMPS registration requires submitting technical files, clinical evidence, and risk management documentation translated into Spanish. Any company placing medical devices on the Spanish market must hold a valid AEMPS import authorisation. The Spanish bioceramics market benefits from a distinctive combination of international manufacturers and specialized domestic companies. Keramat, headquartered in Santiago de Compostela, is the only company in Spain that manufactures reparative surgery bioceramics, specializing in tricalcium phosphate bioceramics for bone implants used in traumatology, orthodontics, and neurology. I.Ceram, a Spanish company, designs, manufactures, and markets innovative ceramic medical implants, including porous alumina ceramic implants used for shoulder, spine, hip, tibia, ankle, and foot prostheses. Nanoker Research has entered the ceramic implant market with INPERIO, an all-ceramic monobloc dental implant made from a Bioceramics composite. Mimetis Biomaterials, based in Barcelona, manufactures MimetikOss®, a biphasic bone graft substitute.

Market Outlook

• According to the research report, "Spain Bioceramics Market Outlook, 2031," published by Bonafide Research, the Spain Bioceramics Market was valued at more than 130 Million in 2025.
• A defining characteristic of Spain's bioceramics market is the country's position as one of the most mature dental implant markets globally, coupled with a decentralized but evolving orthopedic implant surveillance infrastructure. Spain's exceptionally high dental implant penetration with more than 2.1 million implants placed annually and one of the highest per capita rates worldwide reflects the strong clinical adoption of zirconia based bioceramics and the country's advanced dental infrastructure. Following the post pandemic recovery, the Spanish implantology market has entered a phase of sustained growth, having practically reached pre-pandemic volumes. The SEPA 2025 roundtable with industry leaders confirmed that the Spanish implantology market has growth potential supported by three pillars: clinical excellence and evidence sustained by R&D, digitalization in service of predictability, and economic sustainability without degrading quality standards. However, industry leaders caution that future growth will depend not only on volume but on clinical, reputational, and social quality of treatment, with a strong emphasis on protecting patients from low cost implantology models when they entail loss of clinical quality.
• The market also reflects Spain's gradual transition toward comprehensive implant surveillance through regional registries and potential national coordination. The RAGal registry represents a significant step forward in orthopedic implant monitoring, enabling real-time tracking of implant performance and rapid response to health alerts, product withdrawals, and specific follow-ups. The registry's data is expected to generate "high-value knowledge" and position Galicia in a "prominent position within traumatological research". The Spanish Society of Rheumatology reports that more than 11 million adults suffer from some form of rheumatic disease, making it the leading cause of permanent disability due to illness, underscoring the substantial addressable population for bioceramic-based interventions. The growing adoption of digitalization in dental implantology identified as a key consensus point at the SEPA 2025 roundtable is driving demand for CAD/CAM zirconia blocks and digital workflows
• Spain's bioceramics market also benefits from a distinctive domestic manufacturing ecosystem. Keramat, based in Santiago de Compostela, specializes in tricalcium phosphate bioceramics for bone implants used in traumatology, orthodontics, neurology, and veterinary practices. The company has raised $1.15 million in funding from investors including XesGalicia and Unirisco Galicia. I.Ceram is another Spanish manufacturer of ceramic medical implants, producing porous alumina ceramic implants for shoulder, spine, hip, tibia, ankle, and foot prostheses as well as osteosynthesis applications. These domestic manufacturers position Spain as a niche player in the European bioceramics manufacturing landscape.

Market Dynamics

Driver: Mature dental implant market with high per capita penetration and sustained growth trajectory
Spain's bioceramics market is uniquely driven by the country's exceptionally high dental implant penetration, with more than 17 million dental implants placed in the last decade and over 2.1 million placed in 2024 alone. Spain ranks among the countries with the highest number of implants per inhabitant worldwide, reflecting the strong clinical adoption and patient acceptance of implant-based dental restorations. The Spanish implantology market generated approximately €1.7 billion in patient spending in 2024, based on an average implant cost of approximately €800 per implant. The market has entered a phase of sustained growth following the post-pandemic recovery, having practically reached pre-pandemic volumes. Demographic factors population aging, greater longevity with high functional and aesthetic expectations and the consolidation of implantology as a therapeutic option for geriatric patients and those with systemic pathologies continue to drive growth. The growing emphasis on aesthetics in dental care is boosting the use of zirconia bioceramics for implants and restorations.

Challenge: Regional fragmentation of arthroplasty registries and absence of a unified national system
One of the principal challenges facing Spain's bioceramics market is the fragmented nature of arthroplasty surveillance infrastructure. While Spain has multiple arthroplasty registries within the SNS and pioneering regional initiatives such as RAGal, there is currently no unified national registry comparable to those in Sweden, England, or Germany. The lack of a comprehensive national system limits the ability to conduct nationwide implant performance monitoring, identify early warnings of device failures, and compare outcomes across regions. Additionally, Spain's healthcare system faces significant surgical waiting lists, with over 850,000 people on surgical waiting lists as of December 2025 and more than 29,000 patients waiting for knee prosthesis procedures. These waiting times can delay access to bioceramic-based interventions and limit procedural volumes. The market's heavy reliance on imported advanced ceramics and dental implant components also exposes healthcare providers to global supply chain risks.



Trend: Regional arthroplasty registries and evidence-based implant surveillance
Spain is experiencing a significant shift toward comprehensive implant surveillance through the establishment of regional registries and the integration of digital technologies. The RAGal registry, launched in January 2026, represents a pioneering initiative that enables early detection of potential implant failures, identification of complication patterns, and complete traceability of each implant. The registry allows comparison of outcomes between centers and professionals, promotes evidence-based best practices, and facilitates healthcare planning. The registry's data is expected to generate "high-value knowledge" and position Galicia in a "prominent position within traumatological research". SOGACOT aims to promote similar registries in other autonomous communities. In the dental sector, digitalization was identified as a key consensus point at the SEPA 2025 roundtable, with industry leaders emphasizing the importance of digital workflows in delivering predictable, high-quality implant treatments. The growing adoption of CAD/CAM technology, digital implant planning, and patient-specific solutions is driving demand for advanced Bioceramics materials.

Policies

• AEMPS Medical Device Registration and EU MDR Compliance: All implantable Bioceramics medical devices must comply with the EU Medical Device Regulation (MDR) and bear CE marking before they can be marketed and distributed in Spain. The Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) serves as the national competent authority, requiring device registration in the AEMPS database, submission of technical files and clinical evidence translated into Spanish, and designation of an In Country Representative for manufacturers without a Spanish legal entity. Any company placing medical devices on the Spanish market must hold a valid AEMPS import authorisation.
• Royal Decree 192/2023 and AEMPS Marketing Register: Manufacturers must register their devices with the AEMPS Marketing Register as set by Article 18 of Royal Decree 192/2023, excluding custom-made products. The registration process follows a structured pathway that begins with AEMPS database submission and concludes with market approval.
• Regional Arthroplasty Registries (RAGal and Catalonia): Spain's decentralized healthcare system has enabled the development of regional arthroplasty registries. The Registro de Artroplastias de Galicia (RAGal), activated on January 2, 2026, is Spain's first fully computerized regional registry of hip, knee, and shoulder prostheses. Developed by SOGACOT in collaboration with Sergas, RAGal enables early detection of implant failures, identification of complication patterns, and complete implant traceability. Catalonia has a previous registry experience, though not computerized nor including shoulder implants. SOGACOT aims to promote similar registries in other autonomous communities.
• Post Market Surveillance and Medical Device Reporting: Medical device manufacturers, importers, and distributors are required to participate in Spain's post market surveillance framework, reporting adverse events, product defects, and field safety corrective actions to AEMPS. The AEMPS is responsible for control and surveillance of medical devices, inspection and authorization, and combating illegal medical devices.
• Clinical Practice Guidelines and Specialty Society Standards: Utilization of Bioceramics devices in Spain is aligned with evidence based recommendations promoted by national professional organizations including the Sociedad Española de Cirugía Ortopédica y Traumatología (SECOT), the Sociedad Española de Reumatología (SER), and the Sociedad Española de Periodoncia y Osteointegración (SEPA). These organizations provide clinical guidelines and continuing education for orthopedic and dental professionals.

Segment Analysis

Spain Bioceramics Market By Type • Bioinert Ceramics represents the largest product category in Spain, driven by the country's mature orthopedic and dental implant markets. Bioinert ceramics maintain their physical integrity in the body and are ideal for load-bearing applications. Alumina and zirconia femoral heads are widely used in hip replacements, with the RAGal registry enabling tracking of implant performance. In dental applications, zirconia is the material of choice for implants, crowns, and bridges, supported by Spain's position as one of the countries with the highest number of implants per inhabitant worldwide. Over 2.1 million dental implants were placed in Spain in 2024, driving substantial demand for bioinert zirconia components.
• Bioactive Ceramics maintains an important position in Spain, particularly in applications requiring bone bonding, including hydroxyapatite coatings, bioactive glass, and bone graft substitutes. Spanish companies such as Mimetis Biomaterials (MimetikOss®, a biphasic bone graft substitute) and Keramat (tricalcium phosphate bioceramics) are active in this segment. Bioactive ceramics are used in orthopedic and dental bone regeneration applications, with the high prevalence of osteoarthritis affecting 7 million Spaniards driving demand.
• Bioresorbable Ceramics represents the fastest-growing type segment in Spain, driven by increasing demand for temporary implants, bone void fillers, and drug delivery systems. These materials gradually dissolve and are replaced by natural bone, making them particularly valuable in applications where permanent implants are unnecessary. Spanish companies continue to develop innovative bioresorbable solutions for orthopedic and dental applications.

Spain Bioceramics Market By Material
• Zirconia represents the leading material category in Spain, driven by the country's exceptionally high dental implant penetration. Over 2.1 million dental implants are placed annually in Spain, with more than 17 million implants placed in the last decade. Zirconia's superior fracture toughness and aesthetic translucency make it the preferred material for dental implants and restorations. The growing emphasis on aesthetics in dental care and the consolidation of implantology as a therapeutic option for geriatric patients continue to drive zirconia adoption. Nanoker Research's INPERIO all-ceramic monobloc dental implant represents a Spanish innovation in zirconia-based implantology.



• Alumina maintains an important position in Spanish orthopedics, with alumina ceramic heads widely used in hip replacements. I.Ceram, a Spanish company, designs and manufactures porous alumina ceramic implants for shoulder, spine, hip, tibia, ankle, and foot prostheses. Alumina's high hardness and wear resistance make it suitable for load-bearing orthopedic applications.
• Calcium Phosphate is a critical material category encompassing hydroxyapatite and β-tricalcium phosphate for bone graft substitutes and implant coatings. Keramat specializes in tricalcium phosphate bioceramics for bone implants used in traumatology, orthodontics, and neurology. Mimetis Biomaterials manufactures MimetikOss®, a biphasic bone graft substitute containing β-TCP and calcium-deficient hydroxyapatite. The high prevalence of osteoarthritis and the large number of joint replacement procedures drive demand for calcium phosphate-based bone graft materials.
• Calcium Sulfate holds a niche position in the Spanish market, primarily used as a synthetic bone void filler and antibiotic-eluting carrier.
• Others (Carbon-based Ceramic, Bioactive Glass) includes carbon-based ceramics for cardiovascular applications, bioactive glass for bone regeneration, and emerging Bioceramics materials. Spanish research institutions continue to explore novel Bioceramics materials.

Spain Bioceramics Market By Application
• Orthopedics represents the largest application segment in Spain, driven by the substantial burden of osteoarthritis affecting 7 million people and the high volume of joint replacement procedures. Spain ranks among the top European countries for the number of prostheses implanted across all joints. The RAGal registry is collecting comprehensive data on hip, knee, and shoulder prostheses, with the first studies from Spanish arthroplasty databases including 280,201 hip prostheses and 151,814 knee prostheses. Orthopedic applications include ceramic femoral heads, ceramic knee components, calcium phosphate bone grafts, and hydroxyapatite coatings. The leading causes of implant failures infection, aseptic loosening, and periprosthetic fractures highlight the importance of advanced ceramic materials that offer improved wear resistance and biocompatibility.
• Dental represents a significant application segment, with Spain ranking among the countries with the highest number of implants per inhabitant worldwide. Over 2.1 million dental implants were placed in 2024, generating approximately €1.7 billion in patient spending. Zirconia has emerged as the preferred material for implants, crowns, and bridges. The SEPA 2025 roundtable confirmed that the Spanish implantology market has growth potential supported by clinical excellence, digitalization, and economic sustainability. Industry leaders emphasized the importance of protecting patients from low-cost implantology models when they entail loss of clinical quality.
• Biomedical & Others encompasses tissue engineering scaffolds, drug delivery systems, cardiovascular applications, surgical instruments, and wound healing products. Spanish companies such as Keramat and I.Ceram are active in developing innovative Bioceramics solutions for various biomedical applications.

Major Bioceramics Manufacturers Operating in Spain
• Keramat, headquartered in Santiago de Compostela, is the only company in Spain that manufactures reparative surgery bioceramics, specializing in tricalcium phosphate bioceramics for bone implants used in traumatology, orthodontics, neurology, and veterinary practices. The company has raised $1.15 million in funding from XesGalicia and Unirisco Galicia.
• I.Ceram is a Spanish manufacturer of innovative ceramic medical implants, including porous alumina ceramic implants for shoulder, spine, hip, tibia, ankle, and foot prostheses. The company's porous alumina ceramic implants demonstrate intrinsic qualities required for developing treatments for bone infections and bone metastasis.
• Nanoker Research has entered the ceramic implant market with INPERIO, an all-ceramic monobloc dental implant made from a Bioceramics composite.
• Mimetis Biomaterials, based in Barcelona, manufactures MimetikOss®, a biphasic bone graft substitute containing β-TCP and calcium-deficient hydroxyapatite.
• International players with significant presence include Zimmer Biomet, Stryker, Straumann, Dentsply Sirona, and CeramTec. Straumann Iberia is a key player in the Spanish dental implant market.
• The market is also supported by distributors and procurement organizations providing commercialization, maintenance, and supply chain support.

Spain Bioceramics Procedure Economics

• Bioceramics implantation in Spain operates within the decentralized SNS framework, with regional health authorities responsible for service delivery and procurement. Surgical waiting lists remain a significant challenge, with over 850,000 people on surgical waiting lists as of December 2025 and more than 29,000 patients waiting for knee prosthesis procedures.
• In private hospitals and specialized orthopedic centers, the total cost of joint replacement surgery including the ceramic component, hospital charges, surgeon fees, and post-operative management varies depending on hospital category, implant type, and geographic location.
• In the dental sector, the average cost of a dental implant is approximately €800, with the Spanish implantology market generating approximately €1.7 billion in patient spending in 2024. The domestic sell-out market reflects growing patient attention to prevention, aesthetics, and complex rehabilitations.
• Public hospitals provide joint replacement procedures through the SNS, with access depending on clinical eligibility, referral pathways, institutional capacity, and waiting times. The RAGal registry enables complete implant traceability and rapid response to health alerts, supporting patient safety.
• Long-term costs include device monitoring, imaging surveillance, and revision procedures. The RAGal registry's data on implant performance will support evidence-based decision-making for ceramic implant selection.

Spain Bioceramics Market By End User
• Hospitals and Surgical Centers dominate Bioceramics utilization in Spain. The SNS comprises 472 public hospitals (62.6% of all hospital centers), with private hospitals integrated in the SNS having grown 36.8% over the past decade to 145 centers. The RAGal registry collects data from hospitals in Galicia, with the goal of comparing outcomes between centers and professionals.
• Dental Clinics and Laboratories represent a significant end-user category, with Spain ranking among the countries with the highest number of implants per inhabitant worldwide. Over 2.1 million dental implants were placed in 2024. Dental clinics provide patient-facing implant and restorative services, while dental laboratories manufacture crowns, bridges, and custom abutments using CAD/CAM technology. The SEPA 2025 roundtable emphasized the importance of digitalization in delivering predictable, high-quality implant treatments.
• Others includes medical device manufacturers (OEMs), academic research institutions, and biotechnology companies. Spanish companies such as Keramat, I.Ceram, Nanoker Research, and Mimetis Biomaterials represent domestic manufacturing capability in bioceramics and regenerative medicine. Spanish research institutions continue to advance Bioceramics research and development.

Spain Bioceramics Market By Form
• Liquid (Injectable) & Others represents the largest form segment in Spain, driven by growing preference for ready-to-use formulations including injectable bone cements, premixed calcium phosphate pastes, flowable bone graft putties, and pre-sintered dental blocks for CAD/CAM milling. The adoption of digital dentistry technologies in Spain's mature dental implant market supports demand for pre-sintered zirconia blocks.
• Powder maintains an important position as raw material feedstock for OEM manufacturing and on-site mixing for bone graft applications. Powder forms are primarily purchased by medical device manufacturers and hospitals for custom preparation. Spain's import trends for ceramic biomaterials reflect ongoing demand for these materials. Keramat's tricalcium phosphate bioceramics are manufactured in powder and other forms for bone implant applications.

Market Outlook by Healthcare Spending and Infrastructure

• Spain's bioceramics market growth is linked to the country's position as one of the most mature dental implant markets globally and its evolving orthopedic implant surveillance infrastructure. Over 2.1 million dental implants are placed annually, with Spain ranking among the countries with the highest number of implants per inhabitant worldwide.
• The SNS provides universal healthcare coverage through 472 public hospitals and an integrated private hospital network that has grown 36.8% over the past decade. Private healthcare expenditure plays an increasingly important role, especially for dental implants and premium orthopedic procedures.
• The RAGal registry, launched in January 2026, represents a significant advancement in orthopedic implant surveillance, enabling real-time tracking of implant performance and rapid response to health alerts. SOGACOT aims to promote similar registries in other autonomous communities, potentially leading to broader national implant surveillance.
• The future growth opportunity for bioceramics in Spain depends on continued investment in digital health technologies, CAD/CAM dentistry, regional implant registries, and additive manufacturing. The Spanish implantology market's growth trajectory, supported by clinical excellence, digitalization, and economic sustainability, positions Spain as a key European market for Bioceramics technologies. Professional organizations including SECOT, SER, and SEPA continue to advance the field through clinical research, guideline development, and professional education.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Bioceramics Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Type
• Bioinert Ceramics
• Bioactive Ceramics
• Bioresorbable Ceramics

By Material
• Alumina
• Zirconia
• Calcium Phosphate
• Calcium Sulfate
• Others (carbon-based ceramic, Bio activated Glass)

By Application
• Orthopedics
• Dental
• Biomedical & others

By End User
• Hospitals and Surgical Centers
• Dental Clinics and Laboratories
• Others

By Form
• Powder
• Liquid (Injectable) & Others